Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmerging Markets, Led By China, Expected To Keep Sales Growth "Strong" Through 2014, IMS Says

This article was originally published in PharmAsia News

Executive Summary

Growth in "pharmerging" markets is so strong it is likely to nearly offset lost sales from genericization of some of pharma's biggest products in the next two years, IMS Health said April 20

You may also be interested in...



China Approves Merck Serono Orphan Drug Kuvan; Paves Way For More Orphan Drug R&D

China's State FDA has approved Merck Serono's Kuvan (sapropterin) for orphan condition hyperphenylalaninemia in phenylketonuria or BH4 deficiency, a rare congenital metabolic disorder that increases blood phenylalanine levels. The approval underlines opportunities in the Chinese orphan drug market, says a leading Chinese expert

China Approves Merck Serono Orphan Drug Kuvan; Paves Way For More Orphan Drug R&D

China's State FDA has approved Merck Serono's Kuvan (sapropterin) for orphan condition hyperphenylalaninemia in phenylketonuria or BH4 deficiency, a rare congenital metabolic disorder that increases blood phenylalanine levels. The approval underlines opportunities in the Chinese orphan drug market, says a leading Chinese expert

Beyond BRIC: 'Pharmerging' Markets Loom If Pharma Is To Expand -IMS Study

Big Pharma needs to target emerging markets more aggressively - but not just the usual suspects. Brazil, Russia, India and China (BRIC) remain highly important, but in a March 16 report, IMS Health predicts that 17 countries, in total, will contribute 48 percent of annual market growth in 2013, up from 37 percent they contributed last year

Related Content

UsernamePublicRestriction

Register

SC074604

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel